Fort Myers' Mayor to Proclaim June as NeoGenomics' Commitment to Cancer Month
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers' Mayor, Kevin Anderson, will be dedicating June as NeoG
Press Release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the 'Company' or
Form 144 | NeoGenomics(NEO.US) Officer Proposes to Sell 198.34K in Common Stocks
SEC FILLINGS DISCLOSED/ May 28, $NeoGenomics(NEO.US)$ Officer BRUCE K CROWTHER intends to sell 13,882 shares of its common stock on May 28, with a total market value of approximately $198.34K. Sour
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of Clinical
NeoGenomics(NEO.US) Officer Sells US$16,511.26 in Common Stock
$NeoGenomics(NEO.US)$ Officer Olivo Alicia C sold 1,049 shares of common stock on May 15, 2024 at an average price of $15.74 for a total value of $16,511.26.Source: Announcement What is statement of c
Increasing Losses Over Three Years Doesn't Faze NeoGenomics (NASDAQ:NEO) Investors as Stock Rises 5.3% This Past Week
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term NeoGenomics, Inc. (NASDAQ:NEO) shareholders. Unfortunately, they
NeoGenomics Earnings Analysis: Q1 Recap
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.Here's what investors need to know about the latest announcement.EarningsNeoGenomics beat estima
Piper Sandler Gives a Buy Rating to NeoGenomics (NEO)
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript
NeoGenomics Is Maintained at Buy by BTIG
NeoGenomics Is Maintained at Buy by BTIG
Express News | BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Envista Holdings (NVST)
Buy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth Prospects
Express News | Neogenomics Inc : Btig Cuts Target Price to $21 From $23
NeoGenomics Is Maintained at Buy by TD Cowen
NeoGenomics Is Maintained at Buy by TD Cowen
Express News | TD Cowen Maintains Buy on NeoGenomics, Lowers Price Target to $20
NeoGenomics Coverage Assumed by Craig-Hallum at Buy
NeoGenomics Coverage Assumed by Craig-Hallum at Buy
Express News | Craig-Hallum Assumes NeoGenomics at Buy, Announces Price Target of $26
Express News | Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...
No Data